178. J Pharmacol Exp Ther. 2018 May;365(2):354-367. doi: 10.1124/jpet.117.247163. Epub2018 Mar 19.Identification and Characterization of Novel Receptor-InteractingSerine/Threonine-Protein Kinase 2 Inhibitors Using Structural SimilarityAnalysis.Salla M(1), Aguayo-Ortiz R(1), Danmaliki GI(1), Zare A(1), Said A(1), Moore J(1),Pandya V(1), Manaloor R(1), Fong S(1), Blankstein AR(1), Gibson SB(1), GarciaLR(1), Meier P(1), Bhullar KS(1), Hubbard BP(1), Fiteh Y(1), Vliagoftis H(1),Goping IS(1), Brocks D(1), Hwang P(1), Velázquez-Martínez CA(1), Baksh S(2).Author information: (1)Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H.,S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.),Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy andPharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta,Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia,Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.);Departments of Biochemistry and Medical Genetics and Immunology, University ofManitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast CancerResearch Center Chester Beatty Laboratories, London, United Kingdom (L.R.G.,P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada(S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta,Canada (S.B.).(2)Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H.,S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.),Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy andPharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta,Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia,Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.);Departments of Biochemistry and Medical Genetics and Immunology, University ofManitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast CancerResearch Center Chester Beatty Laboratories, London, United Kingdom (L.R.G.,P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada(S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta,Canada (S.B.) sbaksh@ualberta.ca.Receptor-interacting protein kinase 2 (RIP2 or RICK, herein referred to as RIPK2)is linked to the pathogen pathway that activates nuclear factorκ-light-chain-enhancer of activated B cells (NFκB) and autophagic activation.Using molecular modeling (docking) and chemoinformatics analyses, we used theRIPK2/ponatinib crystal structure and searched in chemical databases for smallmolecules exerting binding interactions similar to those exerted by ponatinib.The identified RIPK2 inhibitors potently inhibited the proliferation of cancercells by > 70% and also inhibited NFκB activity. More importantly, in vivoinhibition of intestinal and lung inflammation rodent models suggestseffectiveness to resolve inflammation with low toxicity to the animals. Thus, ouridentified RIPK2 inhibitor may offer possible therapeutic control of inflammationin diseases such as inflammatory bowel disease, asthma, cystic fibrosis, primary sclerosing cholangitis, and pancreatitis.Copyright © 2018 by The Author(s).DOI: 10.1124/jpet.117.247163 PMID: 29555876 